Rupali Insurance Company Limited (DSE:RUPALIINS)
Bangladesh · Delayed Price · Currency is BDT 22.30
-0.10 (-0.45%)
At close: Jul 31, 2025
Inozyme Pharma Income Statement
Financials in millions BDT. Fiscal year is January - December.
Millions BDT. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Premiums & Annuity Revenue | 481.27 | 440.01 | 348.27 | 325.89 | 375.91 | 400.67 | Upgrade |
Total Interest & Dividend Income | 184.27 | 186.71 | 60.96 | 56.42 | 82.37 | 77.45 | Upgrade |
Gain (Loss) on Sale of Investments | -49.87 | -49.87 | -0.98 | -34 | -7.15 | 0.41 | Upgrade |
Other Revenue | 74.88 | 73.71 | 71.48 | 64.75 | 72.7 | 5.62 | Upgrade |
Total Revenue | 690.54 | 650.56 | 479.72 | 413.06 | 523.82 | 484.16 | Upgrade |
Revenue Growth (YoY) | 35.07% | 35.61% | 16.14% | -21.14% | 8.19% | -22.17% | Upgrade |
Policy Benefits | 222.85 | 200.46 | 129.35 | 71.77 | 66.39 | 25.27 | Upgrade |
Policy Acquisition & Underwriting Costs | 85.53 | 85.53 | 64.88 | 56.36 | 23.03 | 19.78 | Upgrade |
Depreciation & Amortization | 30.23 | 30.23 | 33.01 | 33.58 | 36.34 | 19.03 | Upgrade |
Selling, General & Administrative | 222.48 | 198.41 | 184.04 | 163.72 | 188.61 | 248.52 | Upgrade |
Provision for Bad Debts | 5 | 5 | - | - | - | - | Upgrade |
Reinsurance Income or Expense | - | - | -0.04 | -0.06 | -0.1 | 16.93 | Upgrade |
Total Operating Expenses | 566.08 | 519.64 | 411.32 | 325.5 | 314.48 | 295.67 | Upgrade |
Operating Income | 124.45 | 130.92 | 68.4 | 87.56 | 209.34 | 188.49 | Upgrade |
Other Non Operating Income (Expenses) | -3.22 | -3.22 | -3.9 | -3.79 | -3.61 | -5.2 | Upgrade |
EBT Excluding Unusual Items | 121.23 | 127.7 | 64.49 | 83.77 | 205.73 | 183.29 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 1.52 | 2.28 | 0.29 | 0.26 | Upgrade |
Pretax Income | 117.1 | 127.7 | 66.01 | 86.05 | 206.02 | 183.55 | Upgrade |
Income Tax Expense | 49.44 | 51.84 | 13.52 | 11.49 | 48.46 | 37.89 | Upgrade |
Net Income | 67.67 | 75.86 | 52.49 | 74.57 | 157.56 | 145.66 | Upgrade |
Preferred Dividends & Other Adjustments | -4.13 | - | 16.69 | - | - | - | Upgrade |
Net Income to Common | 71.79 | 75.86 | 35.8 | 74.57 | 157.56 | 145.66 | Upgrade |
Net Income Growth | 37.40% | 44.53% | -29.61% | -52.68% | 8.17% | 8.66% | Upgrade |
Shares Outstanding (Basic) | 77 | 77 | 77 | 77 | 77 | 77 | Upgrade |
Shares Outstanding (Diluted) | 77 | 77 | 77 | 77 | 77 | 77 | Upgrade |
Shares Change (YoY) | 13.80% | - | - | - | - | - | Upgrade |
EPS (Basic) | 0.94 | 0.99 | 0.47 | 0.97 | 2.06 | 1.90 | Upgrade |
EPS (Diluted) | 0.94 | 0.99 | 0.47 | 0.97 | 2.06 | 1.90 | Upgrade |
EPS Growth | 163.51% | 111.92% | -51.99% | -52.68% | 8.17% | 8.66% | Upgrade |
Free Cash Flow | -1.4 | 0.77 | 31.25 | 123.87 | 125.01 | 104.34 | Upgrade |
Free Cash Flow Per Share | -0.02 | 0.01 | 0.41 | 1.62 | 1.63 | 1.36 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | Upgrade |
Operating Margin | 18.02% | 20.13% | 14.26% | 21.20% | 39.97% | 38.93% | Upgrade |
Profit Margin | 10.40% | 11.66% | 7.46% | 18.05% | 30.08% | 30.09% | Upgrade |
Free Cash Flow Margin | -0.20% | 0.12% | 6.51% | 29.99% | 23.86% | 21.55% | Upgrade |
EBITDA | 129.16 | 136.21 | 89.72 | 110.14 | 232.18 | 207.52 | Upgrade |
EBITDA Margin | 18.70% | 20.94% | 18.70% | 26.66% | 44.32% | 42.86% | Upgrade |
D&A For EBITDA | 4.71 | 5.29 | 21.33 | 22.59 | 22.84 | 19.03 | Upgrade |
EBIT | 124.45 | 130.92 | 68.4 | 87.56 | 209.34 | 188.49 | Upgrade |
EBIT Margin | 18.02% | 20.13% | 14.26% | 21.20% | 39.97% | 38.93% | Upgrade |
Effective Tax Rate | 42.22% | 40.59% | 20.48% | 13.35% | 23.52% | 20.64% | Upgrade |
Updated Nov 10, 2024. Source: S&P Global Market Intelligence. Insurance template. Financial Sources.